The Molecular Pathogenesis and Targeted Therapies for Cholangiocarcinoma.
Cholangiocarcinoma
Microenvironment
Molecular aberrations
Precision medicine
Targeted therapies
Journal
Surgical pathology clinics
ISSN: 1875-9157
Titre abrégé: Surg Pathol Clin
Pays: United States
ID NLM: 101491209
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
entrez:
1
9
2022
pubmed:
2
9
2022
medline:
8
9
2022
Statut:
ppublish
Résumé
Cholangiocarcinoma (CCA) is a group of malignancies of the bile ducts with high mortality rates and limited treatment options. In the past decades, remarkable efforts have been dedicated toward elucidating the specific molecular signaling pathways and oncogenic loops driving cholangiocarcinogenesis to ultimately develop more effective therapies. Despite some recent advances, an extensive intra- and inter-tumor heterogeneity together with a poorly understood immunosuppressive microenvironment significantly compromises the efficacy of available treatments. Here, we provide a concise review of the latest advances and current knowledge of the molecular pathogenesis of CCA focusing on clinically relevant aberrations as well as future research avenues.
Identifiants
pubmed: 36049834
pii: S1875-9181(22)00032-0
doi: 10.1016/j.path.2022.05.006
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
529-539Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.